Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04765787
Other study ID # TSCL_NFORT-EFFECT_001
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 25, 2020
Est. completion date August 1, 2021

Study information

Verified date November 2021
Source The Searle Company Limited Pakistan
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The global prevalence of Musculoskeletal disorders (MSD) ranges from 14% to as high as 42%. In addition WHO also estimates that 40% of people over the age of 60 years suffer from MSD and about 80% of the people have had low back pain at some point in their life. In Pakistan, to estimate the prevalence of MSD, there is no data available based on the local population. Locally, studies were conducted on the specific subject pools mainly considering the work related musculoskeletal disorders and backache. However, no real data is available for the symptomatic management of painful musculoskeletal disorders in multiple settings to calculate more generalizable results. So this study is planned and if we found good results then it will help physicians to prescribe the above said medicine to all such cases.


Description:

The management of musculoskeletal pain is complex therefore plethora of treatment options are available include non-pharmacological treatments , complementary therapies, and pharmacological interventions. In order to provide optimal care to patients with musculoskeletal pain and ensure the efficient use of healthcare resources, a comprehensive overview of the available evidence for the most effective treatment options for musculoskeletal pain presentations is essential. In this context, an observational study is planned on the efficacy and safety of analgesic combination (i.e Nuberol Forte®). Nuberol Forte® is a combination of muscle relaxant (Orphanedrine) and an analgesic/antipyretic (Paracetamol/Acetaminophen). There are clear indications that the combination of Orphenadrine with Paracetamol may give increased antinociceptive activity and duration of action over and above the use of Orphenadrine or Paracetamol alone.


Read more »

Study Design


Intervention

Drug:
Combination of Paracetamol 650mg + Orphenadrine 50mg
In routine practice for pain , combination of Paracetamol 650 mg + Orphenadrine 50mg prescribed for 7-10 days with follow up and as per physician discretion

Locations

Country Name City State
Pakistan Liaquat National Hospital Karachi Sindh
Pakistan Medicare Hospital Karachi Sindh
Pakistan Patel Hospital Karachi Sindh

Sponsors (1)

Lead Sponsor Collaborator
The Searle Company Limited Pakistan

Country where clinical trial is conducted

Pakistan, 

References & Publications (13)

See more »

Outcome

Type Measure Description Time frame Safety issue
Primary To assess the effectiveness of Nuberol Forte from baseline to 2 weeks the pain, muscle spasm and stiffness are assessed by Muscle & Joint Measure scale. 2 weeks
Primary To assess the safety of Nuberol Forte in the cases presenting with Musculoskeletal disorder Safety is monitored from the first dose of the study drug 2 weeks
See also
  Status Clinical Trial Phase
Completed NCT03334929 - Virtual Reality Distraction for Anxiety Reduction During Trigger Points Procedures in Pain Medicine Clinic N/A
Recruiting NCT06129383 - The Effect of Adding PIFP Block to SAP Block on Postoparative Pain Management in Patient Planned for Breast Surgery N/A
Completed NCT06054945 - Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
Active, not recruiting NCT02276495 - Can Single-Injection Adductor Canal Blocks Improve PostOp Pain Relief in Patients Undergoing Total Knee Arthroplasty? N/A
Completed NCT04094246 - Battlefield Acupuncture Following Shoulder Surgery N/A
Completed NCT05514236 - Effect of Virtual Reality and Music Therapy on Pain Relief in Outpatient Hysteroscopy N/A
Recruiting NCT04809935 - EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy Phase 4
Not yet recruiting NCT05492903 - COMmunity of Practice And Safety Support for Navigating Pain (COMPASS-NP) N/A
Not yet recruiting NCT04328805 - Pain Reduction and Changes in Upper Limb Function Produced by an Ibuprofen Treatment in Carpal Tunnel Syndrome. Phase 4
Completed NCT02922101 - Evaluation of the Effectiveness of an Audit and Feedback Intervention With Quality Improvement Toolbox in Intensive Care N/A
Completed NCT01541293 - Intrauterine Lidocaine for Laminaria Phase 1
Not yet recruiting NCT01059487 - Bringing Acute and Wellness Care to Underserved Populations Using Traditional Chinese Medicine Phase 0
Completed NCT03290378 - Tramadol Versus Placebo in the Management of Postoperative Pain Following Bunionectomy Phase 3
Recruiting NCT05794828 - Erector Spinae Regional Anesthesia for Pain Control Early Phase 1
Active, not recruiting NCT04109885 - Paracervical Injection for Headache in the Emergency Department Phase 2
Recruiting NCT05857202 - Oxidative Stress and Inflammation Biomarkers in Surgically Treated Patients With Laryngeal Cancer
Recruiting NCT03851042 - Virtual Reality for Postoperative Pain After Laparoscopic Hysterectomy N/A
Completed NCT04566536 - NoL Monitor Performances of Nociceptive and Non-nociceptive Stimuli Discrimination During Robotic Surgery
Completed NCT03471390 - Improving Pain Management in Nursing Homes: a Pilot Study N/A
Enrolling by invitation NCT02995278 - Usage and Plan of Care Changes Due to Drug Screenings